Effect of High-calcium Intake on Substrate Metabolism During Exercise

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Javier Gonzalez, Northumbria University
ClinicalTrials.gov Identifier:
NCT01779245
First received: January 28, 2013
Last updated: September 4, 2013
Last verified: September 2013
  Purpose

A high-calcium intake can accelerate fat loss under energy-restricted diets. Part of this may be due to a shift in substrate metabolism where there is an increase in the rate of fat oxidation. However, whether high-calcium intake can influence substrate metabolism during exercise is not known. Accordingly, we aim to investigate the effect of 2 weeks of high-calcium intake on substrate metabolism during exercise.


Condition Intervention
Lipid Metabolism
Dietary Supplement: Calcium
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: The Impact of a Calcium Supplementation on Lipid Metabolism During Exercise.

Resource links provided by NLM:


Further study details as provided by Northumbria University:

Primary Outcome Measures:
  • Substrate metabolism [ Time Frame: 60 s samples every 3 min for 15 min ] [ Designated as safety issue: No ]
    Substrate metabolism will be assessed by the respiratory exchange ratio (rate of carbon dioxide production/rate of oxygen consumption) from samples of expired gas collected during the first 15 minutes of an incremental cycling test.


Secondary Outcome Measures:
  • Plasma non-esterified fatty acid concentrations [ Time Frame: Every 3 min for 15 min ] [ Designated as safety issue: No ]
    Non-esterified fatty acid concentrations will be determined from plasma samples collected during the first 15 minutes of an incremental cycling test to indicate fatty acid availability.

  • Plasma glycerol concentrations [ Time Frame: Every 3 min for 15 min ] [ Designated as safety issue: No ]
    Glycerol concentrations will be determined from plasma samples collected during the first 15 minutes of an incremental cycling test as a marker of lipolysis.


Other Outcome Measures:
  • Serum parathyroid hormone concentration [ Time Frame: Baseline (Pre-post 2 week supplementation) ] [ Designated as safety issue: No ]
    Parathyroid hormone concentrations will be determined at rest before and after supplementation periods as a indicator of calcium status.

  • Plasma glucose-dependent insulinotropic peptide concentration [ Time Frame: Baseline (Pre-post 2 week supplementation) ] [ Designated as safety issue: No ]
    Glucose-dependent insulinotropic peptide concentrations will be determined at rest before and after supplementation periods as a potential mechanism of any changes in metabolism.

  • Plasma glucagon-like peptide-1 concentration [ Time Frame: Baseline (Pre-post 2 week supplementation) ] [ Designated as safety issue: No ]
    Glucagon-like peptide-1 concentrations will be determined at rest before and after supplementation periods as a potential mechanism of any changes in metabolism.


Enrollment: 13
Study Start Date: October 2012
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control
A chocolate milkshake with a normal calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 400 mg calcium per serving).
Dietary Supplement: Placebo
Experimental: High-Calcium
A chocolate milkshake with a high calcium content will be consumed daily (235 kcal; 13 g protein; 42 g carbohydrate; 1 g fat, 1400 mg calcium per serving).
Dietary Supplement: Calcium
Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Physically active (moderate-vigorous exercise >3 time per week)
  • Male
  • 18-40 yrs of age

Exclusion Criteria:

  • Smoker
  • Known Food Allergies
  • Metabolic disorders
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01779245

Locations
United Kingdom
Northumbria University
Newcastle upon Tyne, Tyne and Wear, United Kingdom, NE1 8ST
Sponsors and Collaborators
Northumbria University
Investigators
Principal Investigator: Emma J Stevenson, PhD Northumbria University
  More Information

No publications provided

Responsible Party: Javier Gonzalez, Principal Investigator, Northumbria University
ClinicalTrials.gov Identifier: NCT01779245     History of Changes
Other Study ID Numbers: 32AN3
Study First Received: January 28, 2013
Last Updated: September 4, 2013
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Calcium, Dietary
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 22, 2014